
自引率: 23.3%
被引量: 2041
通过率: 暂无数据
审稿周期: 3.5
版面费用: 暂无数据
国人发稿量: 90
期刊描述简介:
JBUON is an independent Open Access Journal, published by BAKIS Productions LTD, and appears exclusively on the internet. It is covered/indexed in PUBMED/MEDLINE, PUBMED Central, Science Citation Index Expanded (SCIE), SciSearch, Web of Science, Global Health, Current Awareness in Biological Sciences (BIO-BASE), EMBASE/Excerpta Medica, and SCOPUS. JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.
-
Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
被引量:2 发表:2021
-
A dosimetric comparison between volumetric-modulated arc therapy and dynamic conformal arc therapy in SBRT.
被引量:9 发表:2019
-
UNC119 promoted cell growth and migration by Wnt/β-catenin signal and TGF-β/EMT signal pathway in hepatocellular carcinoma.
被引量:1 发表:2018
-
An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
被引量:8 发表:2018
-
The prognostic value of FOXP3+ T regulatory cells in colorectal cancer.
被引量:23 发表:2015